Study period | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Time point | Enrollment | Allocation | Active treatment post allocation | Follow-up | |||||||
Week −1 | Week 0 (Baseline) | Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 10 | Week 14 | |
Enrollment | |||||||||||
Eligibility screening | ○ | ||||||||||
Written informed consent | ○ | ||||||||||
Vital signs | ○ | ○ | ○ | ○ | |||||||
Sociodemographic characteristics, medical history (e.g., LBP, medication history) | ○ | ||||||||||
Physical examination | ○ | ||||||||||
Randomized allocation | ○ | ||||||||||
Interventions | |||||||||||
Treatment in CMT group | ←2–3 times/week → | ←1–3 times/week → | |||||||||
Treatment in UCa group (times/week) | ←2–3 times/week → | ←1–3 times/week → | |||||||||
Treatment in CMT + UCa group (times/week) | ←2–3 times/week → | ←1–3 times/week → | |||||||||
Assessments | |||||||||||
Symptoms and change in medicine | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |||
NRS of LBP and leg pain | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | ○ | |
ODI | ○ | ○ | ○ | ○ | |||||||
PGIC | ○ | ○ | ○ | ||||||||
ROM | ○ | ○ | ○ | ○ | |||||||
EQ-5D | ○ | ○ | ○ | ○ | ○ | ||||||
HUI-III | ○ | ○ | ○ | ○ | ○ | ||||||
Economic evaluation | ○ | ○ | ○ | ○ | ○ | ||||||
Adverse events | ○ | ← every visit → | ○ | ○ | ○ |